Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CEREVEL THERAPEUTICS HOLDINGS, INC.

(CERE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company combines an understanding of disease-related biology and neurocircuitry of the brain with chemistry and central nervous system (CNS), receptor pharmacology to discover and design new therapies. The Company is engaged in the development of new therapies for neuroscience diseases, including schizophrenia, epilepsy and Parkinson’s disease. The Company’s product candidate includes CVL-231, Darigabat, Tavapadon, CVL-871 and CVL-936. The Company’s product candidate CVL-231 for the treatment of schizophrenia. Its Darigabat for the treatment of both epilepsy and anxiety. Its Tavapadon is a dopamine D1/D5 partial agonist for the treatment of early- and late-stage Parkinson’s disease. Its product candidate CVL-871 for the treatment of dementia-related apathy. Its CVL-936 for the treatment of substance use disorder (SUD).

Number of employees : 104 people.
Managers
Name Title Age Since
N. Coles Executive Chairman & Chief Executive Officer 61 -
Abraham Ceesay President 43 2021
Mark Bodenrader VP-Finance, Chief Financial & Accounting Officer 48 2021
John Renger Chief Scientific Officer 52 2019
Raymond Sanchez Chief Medical Officer 60 2019
Morris J. Birnbaum, Dr. Independent Director 69 2018
Douglas Ernest Giordano Independent Director 59 2018
Adam M. Koppel, Dr. Independent Director 51 2018
Marijn Dekkers Independent Director 63 2018
Norbert G. Riedel, Dr. Lead Independent Director 63 2018
Members of the board
Name Title Age Since
N. Coles Executive Chairman & Chief Executive Officer 61 -
Morris J. Birnbaum, Dr. Independent Director 69 2018
Douglas Ernest Giordano Independent Director 59 2018
Adam M. Koppel, Dr. Independent Director 51 2018
Marijn Dekkers Independent Director 63 2018
Norbert G. Riedel, Dr. Lead Independent Director 63 2018
Christopher Gordon Independent Director 48 2018
Gabrielle G. Greene-Sulzberger Independent Director 61 2019
Ruth McKernan, Dr. Independent Director 63 2020
Deval L. Patrick Independent Director 65 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 147,235,789 119,703,891 81.3% 0 0.0% 81.3%
Shareholders
NameEquities%
Bain Capital Private Equity LP 60,632,356 41.2%
Pfizer Inc. 27,349,211 18.6%
Fidelity Management & Research Co. LLC 12,790,586 8.69%
T. Rowe Price Associates, Inc. (Investment Management) 5,840,731 3.97%
Perceptive Advisors LLC 5,086,727 3.45%
The Vanguard Group, Inc. 4,576,684 3.11%
Federated Global Investment Management Corp. 3,113,333 2.11%
Alkeon Capital Management LLC 2,634,707 1.79%
RA Capital Management LP 2,200,000 1.49%
SSgA Funds Management, Inc. 2,161,772 1.47%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Cerevel Therapeutics Holdings, Inc.